The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Pancreatic cancer is an aggressive disease characterized by rapid growth and early metastasis. The recepteur d'origine nantais (RON) receptor tyrosine kinase is overexpressed and/or constitutively active in several epithelial cancers, but its role in pancreatic cancer is unknown. In this study, we have characterized RON expression in both murine and human pancreatic cancer. Immunoblotting indicates that RON is expressed in pancreatic intraepithelial neoplasia (PanIN), primary, and metastatic cell lines both in the human and mouse. Immunostaining revealed that 93% of high-grade PanIN, 79% of primary, and 83% of metastatic lesions from human pancreatic tissue samples expressed RON, with minimal expression in normal ducts and low-grade PanIN (6% and 18%, respectively). Moreover, we show a dose-dependent effect of hepatocyte growth factor-like protein (HGFL), the RON-specific ligand, on pancreatic cancer cell migration and invasion, which was reversed by RON inhibition. Although stimulation with HGFL had no effect on proliferation, concurrent RON receptor blockade and gemcitabine treatment increased apoptosis of RON-expressing pancreatic cancer cells versus gemcitabine treatment alone. Finally, HGFL stimulation of pancreatic cancer cells resulted in increased expression of phospho-mitogen-activated protein kinase and phospho-Akt. Taken together, these findings suggest that RON receptor signaling may contribute to pancreatic carcinogenesis, and that further investigation is warranted to assess the potential of RON-directed therapies in this deadly disease.

[1]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Collins,et al.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. , 2006, Cancer research.

[3]  Yuan Cheng,et al.  Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. , 2006, Cancer research.

[4]  T. Blundell,et al.  Crystal structure of the β‐chain of human hepatocyte growth factor‐like/macrophage stimulating protein , 2005, The FEBS journal.

[5]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[6]  Helen H. W. Chen,et al.  Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients , 2005, Clinical Cancer Research.

[7]  M. Collins,et al.  Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. , 2005, Cancer research.

[8]  R. Wolff,et al.  Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Bold,et al.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. , 2004, Journal of the American College of Surgeons.

[10]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[11]  B. Peace,et al.  Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. , 2003, Experimental cell research.

[12]  R. Bold,et al.  AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 , 2003, British Journal of Cancer.

[13]  A. Potti,et al.  HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. , 2003, Anticancer research.

[14]  A. Danilkovitch-Miagkova.  Oncogenic signaling pathways activated by RON receptor tyrosine kinase. , 2003, Current cancer drug targets.

[15]  L. Fu,et al.  Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. , 2002, Carcinogenesis.

[16]  Ming-Hai Wang,et al.  Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo , 2002, Oncogene.

[17]  Ming-Hai Wang,et al.  Activation of the RON receptor tyrosine kinase protects murine macrophages from apoptotic death induced by bacterial lipopolysaccharide , 2002, Journal of leukocyte biology.

[18]  B. Peace,et al.  Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis , 2001, Oncogene.

[19]  J. Testa,et al.  AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. , 2001, Cancer research.

[20]  T. Mattfeldt,et al.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. , 2001, Genes & development.

[21]  C. Yeo,et al.  The molecular genetics of pancreatic ductal carcinoma: a review. , 2000, Surgical oncology.

[22]  M. Tsao,et al.  Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2000, Cancer research.

[23]  M. H. Wang,et al.  Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. , 2000, Carcinogenesis.

[24]  T. Suda,et al.  Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. , 1999, International journal of oncology.

[25]  A. Danilkovitch,et al.  Kinases involved in MSP/RON signaling , 1999, Journal of leukocyte biology.

[26]  E. Leonard,et al.  Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. , 1998, The Journal of investigative dermatology.

[27]  E. Air,et al.  Functional Characterization of Domains Contained in Hepatocyte Growth Factor-like Protein* , 1997, The Journal of Biological Chemistry.

[28]  S. Dergham,et al.  Relationship of family cancer history to the expression of P53, P21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[29]  F. Sarkar,et al.  HER‐2/neu Expression in Pancreatic Adenocarcinoma: Relation to Tumor Differentiation and Survival , 1997, Pancreas.

[30]  A. Iwama,et al.  STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. , 1996, The EMBO journal.

[31]  P. Comoglio,et al.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype , 1996, Molecular and cellular biology.

[32]  T. Suda,et al.  Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. , 1996, Experimental cell research.

[33]  E. Leonard,et al.  Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. , 1996, The Journal of clinical investigation.

[34]  S. Goodman,et al.  Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. , 1996, Human pathology.

[35]  E. Leonard,et al.  Identification of the ron gene product as the receptor for the human macrophage stimulating protein. , 1994, Science.

[36]  L. Naldini,et al.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. , 1994, The EMBO journal.

[37]  D. Witte,et al.  Hepatocyte‐specific expression of the mouse hepatocyte growth factor–like protein , 1993, Hepatology.

[38]  M. Mattei,et al.  A novel putative receptor protein tyrosine kinase of the met family. , 1993, Oncogene.

[39]  M. Collins,et al.  - Catenin Activation β Highly Metastatic Mammary Tumors Associated with Mammary-Specific Ron Receptor Overexpression Induces , 2006 .

[40]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.